Welcome to our dedicated page for Sarepta Therapeutics SEC filings (Ticker: SRPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sarepta Therapeutics, Inc. (SRPT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sarepta is a biotechnology issuer listed on the NASDAQ Global Select Market, and its filings offer detailed insight into its precision genetic medicine business, capital structure and risk profile.
For investors analyzing SRPT, Forms 10-K and 10-Q (when available) describe Sarepta’s focus on rare diseases, including Duchenne muscular dystrophy, and its portfolio of RNA-targeted and gene transfer therapies. These periodic reports typically discuss marketed products such as ELEVIDYS and PMO exon-skipping therapies, outline research and development priorities across muscle, central nervous system and cardiac diseases, and present management’s view of key risks and uncertainties.
Current reports on Form 8-K are particularly relevant for Sarepta, as they document material events such as exchange transactions involving its 1.25% Convertible Senior Notes due 2027 and new 4.875% Convertible Senior Notes due 2030, private placements of common stock, strategic restructuring actions and executive transitions. These filings also reference press releases that announce quarterly financial results, clinical trial milestones, FDA decisions on ELEVIDYS labeling, and clinical holds affecting certain limb girdle muscular dystrophy gene therapy programs.
Users interested in capital markets activity and potential dilution can review disclosures about unregistered sales of equity securities, convertible note terms, and related exchange agreements. Over time, proxy statements and other governance-related filings can provide additional detail on board structure and compensation policies.
Stock Titan enhances these SRPT filings with AI-powered summaries that explain complex sections in plain language, highlight key changes from prior periods and surface items such as revenue drivers, pipeline updates and financing terms. Real-time updates from EDGAR, along with structured access to Form 4 insider transaction reports when filed, help investors monitor how Sarepta’s regulatory disclosures evolve as its genetic medicine programs progress.
Sarepta Therapeutics EVP and General Counsel Cristin Rothfuss reported a small share disposition for tax withholding purposes. On March 2, 2026, 408 shares of Sarepta common stock were withheld by the company at $16.20 per share to cover taxes on restricted stock units that vested from a grant made on March 1, 2024. After this tax-withholding transaction, Rothfuss’s directly held ownership stood at 139,348 shares of common stock.
Sarepta Therapeutics, Inc. Chief Financial Officer Ryan Ho-Yan Wong reported a tax-related share disposition linked to restricted stock vesting. On March 2, 2026, 450 shares of common stock were withheld by the company at $16.20 per share to cover tax withholding obligations from restricted stock units granted on March 1, 2024. After this withholding transaction, Wong directly owned 135,595 shares of Sarepta common stock.
Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan reported equity award activity tied to prior grants. On March 1, 2026, 8,125 Performance Stock Units earned under a March 1, 2024 award were converted into 8,125 shares of common stock as they vested based on milestone achievement.
To cover tax withholding on the vesting of this PSU award and related restricted stock units, the company withheld a total of 4,176 shares of common stock on March 2, 2026, valued at $16.20 per share, as tax-withholding dispositions. After these non‑market transactions, Estepan directly owned 204,699 common shares.
Sarepta Therapeutics, Inc. president of R&D and Tech Ops Louise Rodino-Klapac reported equity compensation activity. On March 1, 2026, 8,125 Performance Stock Units previously earned under a March 1, 2024 PSU award vested and were converted into the same number of common shares, based on the compensation committee’s milestone achievement determination. On March 2, 2026, the company withheld 3,718 and 767 common shares, respectively, at $16.20 per share to cover tax withholding obligations related to the vesting of PSU and RSU awards, leaving Rodino-Klapac with 227,670 directly held common shares.
Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan exercised stock options and acquired additional common shares. On February 26, 2026, he exercised options for 2,069 shares and 5,381 shares of common stock at an exercise price of $13.71 per share. These transactions increased his directly held common stock to 200,750 shares, according to the filing footnote, and involved no reported open-market sales.
Sarepta Therapeutics is a commercial-stage biopharma company focused on RNA-targeted drugs, siRNA therapies and gene therapies for rare neuromuscular diseases, led by Duchenne muscular dystrophy.
The company sells four approved Duchenne products—EXONDYS 51, VYONDYS 53, AMONDYS 45 and the gene therapy ELEVIDYS—and recorded $1,864.3 million in product net revenues for the year ended December 31, 2025, up from $1,788.0 million in 2024 and $1,144.9 million in 2023.
2025 brought significant challenges. Top-line results from the ESSENCE confirmatory trial for VYONDYS 53 and AMONDYS 45 did not meet the primary endpoint, and Sarepta plans further FDA discussions on their approval status. ELEVIDYS was temporarily suspended in the U.S. after serious safety events, later resuming only for ambulatory patients and gaining a boxed warning for acute liver injury and acute liver failure while the non-ambulatory indication was removed from labeling.
The FDA also placed a clinical hold on Sarepta’s LGMD gene therapy trials after a patient death, with SRP‑9003’s path now contingent on additional sirolimus data. At the same time, Sarepta entered a large siRNA collaboration with Arrowhead, paying a $500.0 million upfront fee plus substantial milestones and royalties, and continues to partner with Roche on ELEVIDYS ex-U.S. and with Catalent and Aldevron for manufacturing.
Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan reported an equity compensation transaction involving performance stock units. He acquired 1,875 performance stock units on February 25, 2026 as a grant/award, bringing his directly held performance stock units to 8,125.
According to the disclosure, these 1,875 shares represent units earned under a performance stock unit award originally granted on March 1, 2024, based on the compensation committee’s determination of the company’s achievement of specified milestones. The earned units are scheduled to vest on March 1, 2026, if he continues to provide service to the company through that date.
Sarepta Therapeutics, Inc. reported that executive Louise Rodino-Klapac, President of R&D and Tech Ops, acquired 1,875 Performance Stock Units (PSUs) on the basis of a prior equity award. These PSUs were earned under a PSU grant originally awarded on March 1, 2024.
The number of PSUs earned reflects the compensation committee’s assessment of the company’s achievement of specified milestones in that award. Following this transaction, Rodino-Klapac holds a total of 8,125 PSUs. The earned PSUs are scheduled to vest on March 1, 2026, provided she continues to serve the company through that date.
Sarepta Therapeutics, Inc. reported that Chief Executive Officer Douglas Ingram has decided to retire. On February 25, 2026, he informed the company that he plans to step down by the end of 2026 or once a successor is appointed.
The company has begun a formal search process, considering both internal and external candidates to identify its next CEO. This filing does not discuss changes to the company’s strategy or operations, focusing solely on the planned leadership transition timeline.
Sarepta Therapeutics reported strong 2025 revenue growth but a sharp swing to losses as it invested heavily in gene therapy and RNAi programs. Full-year revenue rose to $2,198.2M from $1,902.0M, driven by ELEVIDYS and higher collaboration and manufacturing revenue, including milestones from Roche and Japan.
Despite this, Sarepta posted a GAAP net loss of $713.4M versus $235.2M of net income in 2024, with diluted EPS moving from $2.34 to a loss of $7.13. The decline reflects a surge in cost of sales, including a $165.3M inventory reserve and additional write-offs, plus research and development expenses of $1,522.1M tied to the Arrowhead DM1 collaboration and milestones.
Year-end cash, cash equivalents and investments were $953.8M. Sarepta refinanced $291.4M of 2027 convertible notes into 2030 notes with cash, reducing near-term maturities. Management highlighted positive three-year EMBARK data for ELEVIDYS, launch in Japan via Chugai, and advancement of multiple siRNA programs, and said it anticipates remaining profitable and cash-flow positive in 2026.